3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lymphoma, Follicular
8
Sarcoma
3
Lymphoma, B-Cell
3
Lymphoma
3
Prostatic Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Rhabdoid Tumor
1
Recurrence
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Inhibition, Psychological
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Colorectal Neoplasms
1
Chordoma
1
Interventions
Gemcitabine
406
Oxaliplatin
131
Fluorouracil
125
130-nm albumin-bound paclitaxel
108
Capecitabine
100
Albumin-Bound Paclitaxel
90
Leucovorin
88
Irinotecan
87
Radiotherapy
76
Radiosurgery
64
Taxes
63
Cisplatin
56
Erlotinib Hydrochloride
44
Drug Therapy
42
folfirinox
40
Magnetic Resonance Spectroscopy
39
pembrolizumab
35
Blood Specimen Collection
33
S 1 (combination)
31
Pancreaticoduodenectomy
31
Docetaxel
31
Nivolumab
30
Bevacizumab
30
Biopsy
26
Surgical Procedures, Operative
25
Cyclophosphamide
25
irinotecan sucrosofate
24
Specimen Handling
24
Radiation
22
Standard of Care
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Neoplasms
×
tazemetostat
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled